Free Trial

Regeneron Pharmaceuticals (REGN) 10K Form and Latest SEC Filings 2026

Regeneron Pharmaceuticals logo
$709.10 -11.95 (-1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$708.05 -1.05 (-0.15%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Regeneron Pharmaceuticals SEC Filings & Recent Activity

Regeneron Pharmaceuticals (NASDAQ:REGN) has submitted 513+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Regeneron Pharmaceuticals's financial statements. The most recent filing was a Form SCHEDULE 13G submitted on April 30, 2026.

Form 4
REGENERON PHARMACEUTICALS, INC. Reports Ownership Change on Apr. 3, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Regeneron Pharmaceuticals Files Current Report on Apr. 29, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Regeneron Pharmaceuticals Files Quarterly Report on Apr. 29, 2026

The 10-Q contains Regeneron Pharmaceuticals's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Regeneron Pharmaceuticals SEC Filing History

Browse Regeneron Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/30/2026 12:03 PM
Regeneron Pharmaceuticals (872589) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/29/2026 5:54 AM
Regeneron Pharmaceuticals (872589) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2026 5:50 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 3:02 PM
Regeneron Pharmaceuticals (872589) Filer
Form DEF 14A
04/24/2026 3:04 PM
Regeneron Pharmaceuticals (872589) Filer
Form DEFA14A
04/08/2026 6:05 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/03/2026 3:01 PM
Regeneron Pharmaceuticals (872589) Issuer
RYAN ARTHUR F (1187443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 10:37 AM
Regeneron Pharmaceuticals (872589) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/03/2026 3:01 PM
Regeneron Pharmaceuticals (872589) Issuer
RYAN ARTHUR F (1187443) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/23/2026 3:55 PM
Regeneron Pharmaceuticals (872589) Issuer
Zoghbi Huda Y (1681643) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2026 8:08 AM
Regeneron Pharmaceuticals (872589) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
01/30/2026 5:51 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/12/2026 5:48 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2026 11:03 AM
Bassler Bonnie L (1683607) Reporting
Regeneron Pharmaceuticals (872589) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:16 PM
Guarini Kathryn (1992352) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:16 PM
Regeneron Pharmaceuticals (872589) Issuer
SING GEORGE L (1225471) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:18 PM
Regeneron Pharmaceuticals (872589) Issuer
Thompson Craig B. (1423419) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:03 PM
POON CHRISTINE A (1189014) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:08 PM
Bassler Bonnie L (1683607) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 4:53 PM
Regeneron Pharmaceuticals (872589) Issuer
SCHLEIFER LEONARD S (1218629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 4:54 PM
Regeneron Pharmaceuticals (872589) Issuer
YANCOPOULOS GEORGE (1226690) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/31/2025 4:05 PM
Regeneron Pharmaceuticals (872589) Issuer
SING GEORGE L (1225471) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:27 PM
Regeneron Pharmaceuticals (872589) Issuer
YANCOPOULOS GEORGE (1226690) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:30 PM
McCourt Marion (1663758) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:32 PM
MURPHY ANDREW J (1796226) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:34 PM
Regeneron Pharmaceuticals (872589) Issuer
Van Plew Daniel P (1411984) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2025 3:23 PM
Regeneron Pharmaceuticals (872589) Issuer
SCHLEIFER LEONARD S (1218629) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 4:38 PM
Pitofsky Jason (2009236) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:31 PM
Regeneron Pharmaceuticals (872589) Issuer
Van Plew Daniel P (1411984) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:08 PM
Fenimore Christopher R. (1697422) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:09 PM
LAROSA JOSEPH J (1238303) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:10 PM
McCourt Marion (1663758) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/24/2025 3:07 PM
LAROSA JOSEPH J (1238303) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 1:31 PM
Bassler Bonnie L (1683607) Reporting
Regeneron Pharmaceuticals (872589) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/07/2025 4:06 PM
Pitofsky Jason (2009236) Reporting
Regeneron Pharmaceuticals (872589) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/07/2025 3:55 PM
Regeneron Pharmaceuticals (872589) Filer
Form 13F-HR
Initial Quarterly Form 13F Holdings report filed by institutional managers
10/31/2025 3:09 PM
POON CHRISTINE A (1189014) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 3:06 PM
MURPHY ANDREW J (1796226) Reporting
Regeneron Pharmaceuticals (872589) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/29/2025 3:36 PM
POON CHRISTINE A (1189014) Reporting
Regeneron Pharmaceuticals (872589) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/28/2025 5:50 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/28/2025 5:56 AM
Regeneron Pharmaceuticals (872589) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/06/2025 6:00 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2025 11:11 AM
FMR LLC (315066) Filed by
Regeneron Pharmaceuticals (872589) Subject
Form SCHEDULE 13G/A
08/01/2025 5:56 AM
Regeneron Pharmaceuticals (872589) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2025 5:49 AM
Regeneron Pharmaceuticals (872589) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2025 10:11 AM
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
Regeneron Pharmaceuticals (872589) Subject
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Regeneron Pharmaceuticals SEC Filings - Frequently Asked Questions

Regeneron Pharmaceuticals (REGN) has submitted 513+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Regeneron Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Regeneron Pharmaceuticals's financial statements page.

The most recent filing was a Form SCHEDULE 13G submitted on April 30, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:REGN) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners